Provided by Tiger Fintech (Singapore) Pte. Ltd.

Phio Pharmaceuticals

2.74
+0.23009.16%
Post-market: 2.64-0.1007-3.68%19:59 EDT
Volume:49.54M
Turnover:159.44M
Market Cap:13.15M
PE:-0.29
High:3.48
Open:3.02
Low:2.51
Close:2.51
Loading ...

Phio Pharmaceuticals Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
05 Jun

Phio Pharmaceuticals assumed with a Buy at H.C. Wainwright

TIPRANKS
·
05 Jun

Robert J. Bitterman, Chairman, President & CEO, Acquires Common Shares of Phio Pharmaceuticals Corp

Reuters
·
23 May

Director Robert L. Ferrara Reports Acquisition of Common Shares of Phio Pharmaceuticals Corp

Reuters
·
22 May

Phio Pharmaceuticals Corp. to Participate in Sidoti Micro-Cap Virtual Investor Conference

Reuters
·
19 May

Phio Pharma Q1 EPS $(0.47) Down From $(0.41) YoY

Benzinga
·
16 May

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile
·
01 May

PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose

Zacks
·
10 Apr

Crude Oil Down 4%; Neogen Shares Plunge After Q3 Results

Benzinga
·
10 Apr

Phio Pharmaceuticals Potential Skin Cancer Treatment Recommended for Dose Escalation

MT Newswires Live
·
09 Apr

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Newsfile
·
09 Apr

Phio Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
08 Apr

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Newsfile
·
03 Apr

Phio Pharmaceuticals Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Apr

Phio Pharmaceuticals Corp expected to post a loss of $1.23 a share - Earnings Preview

Reuters
·
29 Mar

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Newsfile
·
10 Mar

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Newsfile
·
05 Mar

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile
·
26 Feb

Phio Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Feb

Positive Outlook for Phio Pharmaceuticals: Promising Clinical Results and Innovative Technology Drive Buy Rating

TIPRANKS
·
19 Feb